Richardson Electronics (RELL) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
8 Jul, 2026Executive summary
Q1 FY2026 net sales rose 1.6% year-over-year to $54.6 million, with growth in PMT and Canvys segments, partially offset by GES and the impact of the healthcare business sale.
Net income for Q1 FY2026 was $1.9 million, up from $0.6 million in Q1 FY2025, and diluted EPS increased to $0.13 from $0.04.
Excluding healthcare, net sales increased 6.8% year-over-year, marking the fifth consecutive quarter of year-over-year sales growth.
Positive operating cash flow was generated for the sixth consecutive quarter, with a strong cash position of $35.7 million and no outstanding debt.
Strategic focus on engineered solutions, global expansion, and growth in green energy and semiconductor markets.
Financial highlights
Gross margin improved to 31.0% from 30.6% year-over-year, driven by margin expansion in PMT and GES.
Operating income increased to $1.0 million from $0.3 million year-over-year.
EBITDA reached $3.3 million, up from $1.7 million in the prior year.
Backlog at Q1 FY2026 was $134.7 million, up over 125% since FY2019.
Operating expenses as a percentage of net sales improved to 29.2% from 30.0% year-over-year.
Outlook and guidance
Expect continued growth in PMT and GES, with strong momentum in wind and semiconductor segments and expansion into the EU.
Anticipate double-digit growth in GES for FY2026, driven by repowering initiatives and green energy demand.
Operating expenses expected to rise only slightly over FY2025 as investments focus on engineering and green energy expansion.
Healthcare segment sales will remain lower through Q3 FY2026 due to the DirectMed transaction, with positive contribution expected in Q4.
Management expects existing liquidity and cash flow to meet capital and working capital needs for the next twelve months.
Latest events from Richardson Electronics
- Record revenue, margin gains, and backlog growth support positive FY27 outlook and dividend.RELL
Q4 202625 Jul 2026 - Q2 FY25 sales up 12.1% to $49.5M, led by 129% GES growth and improved margins.RELL
Q2 20258 Jul 2026 - Q1 FY25 sales up 2.2% to $53.7M, with strong GES and Healthcare growth and a $137.4M backlog.RELL
Q1 20258 Jul 2026 - Q2 FY26 sales up 5.7% to $52.3M, GES up 39%, backlog $135.7M, $0.06 dividend, no debt.RELL
Q2 202613 Apr 2026 - Q3 FY26 delivered 3.1% sales growth, profitability, and record backlog, led by PMT segment gains.RELL
Q3 202612 Apr 2026 - Sales and profits fell in 2024, but margin, cash flow, and backlog support a positive 2025 outlook.RELL
Q4 20242 Feb 2026 - Q3 net sales up 2.7% YoY, strong PMT/Canvys, $4.9M Healthcare loss, cash $36.7M, no debt.RELL
Q3 202516 Jan 2026 - Shareholders will vote on director elections, auditor ratification, compensation, and capital structure changes.RELL
Proxy Filing1 Dec 2025 - Proxy seeks approval for director elections, auditor, compensation, and share increases.RELL
Proxy Filing1 Dec 2025